Mastzelltumoren der Haut beim Hund – Erste Erfahrungen zum Einsatz von Tigilanoltiglat

Für die Therapie des Mastzelltumors beim Hund steht seit einigen Monaten eine neue Therapie zur Verfügung: die intratumorale Tigilanoltiglat-Injektion. Informieren Sie sich über etablierte Therapieoptionen sowie über das Procedere und erste Erfahrungen mit der neuartigen Therapie.

• Literatur

• 1 Brodey RS. Canine and feline neoplasia. Adv Vet Sci Comp Med 1970; 14: 309-354
• 2 Bostock DE. Neoplasms of the skin and subcutaneous tissues in dogs and cats. Br Vet J 1986; 142 (01) 1-19
• 3 Śmiech A, Ślaska B, Łopuszyński W. et al. Epidemiological assessment of the risk of canine mast cell tumours based on the Kiupel two-grade malignancy classification. Acta Vet Scand 2018; 60 (01) 70
• 4 Shoop SJW, Marlow S, Church DB. et al. Prevalence and risk factors for mast cell tumours in dogs in England. Canine Genet Epidemiol 2015; 2 (01) 1
• 5 London CA, Thamm DH. Mast Cell Tumors. In: Withrow SJ, Vail DM, Page RL. eds. Withrow and MacEwenʼs Small Animal Clinical Oncology. 5^th ed. Riverport Lane St. Louis, Missouri: Elsevier Saunders; 2013: 335-355
• 6 Mullins MN, Dernell WS, Withrow SJ. et al. Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998–2004). J Am Vet Med Assoc 2006; 228 (01) 91-95
• 7 Pelt DR, Fowler JD, Leighton FA. Multiple cutaneous mast cell tumors in a dog: a case report and brief review. Can Vet J 1986; 27 (07) 259-263
• 8 Baker-Gabb M, Hunt GB, France MP. Soft tissue sarcomas and mast cell tumours in dogs; clinical behaviour and response to surgery. Aust Vet J 2003; 81 (37) 732-738
• 9 Kiupel M, Camus M. Diagnosis and prognosis of canine cutaneous mast cell tumors. Vet Clin North Am Small Anim Pract 2019; 49 (05) 819-836
• 10 Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumour: morphologic grading and survival time in 83 dogs. Vet Pathol 1984; 21 (01) 469-474
• 11 Kiupel M, Webster JD, Bailey KL. et al. Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Vet Pathol 2011; 48 (01) 147-155
• 12 Blackwood L, Murphy S, Buracco P. et al. European consensus document on mast cell tumours in dogs and cats. Vet Comp Oncol 2012; 10 (03) e1-e29
• 13 Govier SM. Principles of treatment for mast cell tumors. Clin Tech Small Anim Pract 2003; 18 (02) 103-106
• 14 Selmic LE, Ruple A. A systematic review of surgical margins utilized for removal of cutaneous mast cell tumors in dogs. BMC Vet Res 2020; 16 (01) 1-6
• 15 McCaw DL, Miller MA, Ogilvie GK. et al. Response of canine mast cell tumors to treatment with oral prednisone. J Vet Intern Med 1994; 8 (06) 406-408
• 16 Stanclift RM, Gilson SD. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc 2008; 232 (01) 53-62
• 17 EMA. Produktinformationen: Stelfonta. Im Internet (Stand 31.08.2020): https://www.ema.europa.eu/en/documents/product-information/stelfonta-epar-product-information_de.pdf
• 18 Boyle GM, DʼSouza MM, Pierce CJ. et al. Intra-lesional injection of the novel PKC activator EBC-46 rapidly ablates tumors in mouse models. PloS One 2014; 9 (10) e108887
• 19 De Ridder TR, Campbell JE, Burke-Schwarz C. et al. Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46). J Vet Intern Med. 2020
• 20 Hottendorf GH, Nielsen SW. Canine mastocytoma – a review of clinical aspects. J Am Vet Med Assoc 1969; 154 (08) 917-924